Diagnostic Radioisotopes Market Report 2026

The diagnostic radioisotopes market size has grown strongly in recent years. It will grow from $6.08 billion in 2025 to $6.67 billion in 2026 at a compound annual growth rate (CAGR) of 9.7%. The growth in the historic period can be attributed to growth in cancer diagnosis rates, expansion of nuclear imaging facilities, reliance on technetium-based imaging, limited isotope production centers, hospital-based imaging dominance.

The diagnostic radioisotopes market size is expected to see strong growth in the next few years. It will grow to $9.26 billion in 2030 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to increase in oncology imaging demand, expansion of cardiac nuclear diagnostics, new radioisotope development, regional isotope production investments, aging population diagnostics needs. Major trends in the forecast period include increasing use of pet and spect imaging, rising demand for oncology radioisotopes, expansion of nuclear medicine diagnostics, growing adoption of short-half-life isotopes, improved radiopharmaceutical supply chains.

The growing global burden of cancer is expected to drive the growth of the diagnostic radioisotopes market in the coming years. Cancer is a disease marked by the uncontrolled proliferation of abnormal cells that can invade surrounding tissues and spread throughout the body. The increase in cancer cases worldwide is driven by demographic changes such as population growth and aging, along with greater exposure to risk factors including tobacco use, obesity, and environmental pollutants. Diagnostic radioisotopes play a critical role in healthcare by enabling accurate imaging, early cancer detection, and effective monitoring of disease progression and treatment response. For instance, in October 2025, according to the National Health Service (NHS), a UK-based government health authority, there were 354,820 new cancer diagnoses recorded in 2023, averaging 972 cases per day, which was 8,605 more than in 2022. Therefore, the rising global cancer burden is driving the expansion of the diagnostic radioisotopes market.

Major companies operating in the diagnostic radioisotopes market are focusing on advanced developments such as next-generation positron emission tomography (PET) radiotracers to improve diagnostic accuracy, early detection, and clinical decision-making. Next-generation PET radiotracers are engineered radioactive imaging agents that bind to specific molecular or metabolic targets, enabling high-resolution visualization of tumors and metastatic lesions. For instance, in July 2024, Radiopharm Theranostics Limited, an Australia-based radiopharmaceutical and theranostics developer, received U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) approval for F18-Pivalate (RAD 101), a Fluorine-18 labeled PET imaging agent designed to detect suspected recurrent brain metastases by targeting fatty acid synthase (FASN), which is overexpressed in solid tumors. The radiotracer offers high tumor-to-background contrast, favorable imaging kinetics, and compatibility with existing PET systems, enhancing diagnostic precision and supporting improved clinical decision-making in oncology.

In April 2024, Telix Pharmaceuticals Limited, an Australia-based biotechnology company, acquired ARTMS for an undisclosed amount. Through this acquisition, Telix aims to strengthen its isotope production capabilities and supply chain by leveraging ARTMS’ cyclotron-based radioisotope manufacturing expertise, thereby enhancing its market position and ability to meet growing demand for diagnostic and therapeutic radioisotopes. ARTMS is a Canada-based provider specializing in radioisotope technologies for diagnostic applications.

Major companies operating in the diagnostic radioisotopes market are Cardinal Health Inc., Lantheus Holdings, Curium Pharma, Clarity Pharmaceuticals, Bracco Diagnostic Inc., Nordion Inc., Eckert & Ziegler AG, NorthStar Medical Radioisotopes LLC, NTP Radioisotopes SOC Ltd, Isotopia Molecular Imaging Ltd, Cyclopharm Limited, Trasis NV, ARTMS Inc, Radiomedix Inc, Coqu RadioPharmaceuticals Corp, ANSTO, IRE Institute for Radioelements, NRG, China National Nuclear Corporation, Polatom, Niowave Inc, JSC Isotope, Center of Molecular Research, Oak Ridge National Laboratory, SHINE Technologies.

North America was the largest region in the diagnostic radioisotopes market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the diagnostic radioisotopes market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the diagnostic radioisotopes market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the diagnostic radioisotopes market by increasing costs of imported isotopes, cyclotron equipment, and radiopharmaceutical processing materials. Hospitals and diagnostic imaging centers in developed regions are most affected due to reliance on imported radioisotopes, while emerging markets face supply constraints. These tariffs increase imaging costs. However, they encourage domestic isotope production and regional nuclear medicine infrastructure development.

The diagnostic radioisotopes market research report is one of a series of new reports that provides diagnostic radioisotopes market statistics, including diagnostic radioisotopes industry global market size, regional shares, competitors with a diagnostic radioisotopes market share, detailed diagnostic radioisotopes market segments, market trends and opportunities, and any further data you may need to thrive in the diagnostic radioisotopes industry. This diagnostic radioisotopes market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Diagnostic radioisotopes are radioactive isotopes used in nuclear medicine to diagnose and monitor a wide range of medical conditions. These isotopes emit radiation through radioactive decay, which is captured by specialized imaging equipment to produce detailed images of internal body structures and evaluate organ function.

The main diagnostic radioisotopes include technetium-99m, thallium-201, gallium-67, iodine-123, fluorodeoxyglucose (FDG), rubidium-82, and others. Technetium-99m is widely used in medical imaging because of its favorable nuclear characteristics and broad availability. Imaging modalities include single-photon emission computed tomography (SPECT), positron emission tomography (PET), and beta-emitter-based techniques, which are applied across areas such as oncology, cardiology, and other medical fields.

The diagnostic radioisotopes market consists of revenues earned by entities by providing services such as radiopharmacy services, imaging services, radioisotope production and supply, diagnostic procedures, and theranostics. The market value includes the value of related goods sold by the service provider or included within the service offering. The diagnostic radioisotopes market also includes sales of products including Indium-111, Xenon-133, Molybdenum-99, and Phosphorus-32. Values in this market are 'factory gate values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.